Radiofrequency ablation of hepatocellular carcinoma

S. A. Curley, F. Izzo

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The majority of patients with primary or metastatic hepatic tumors are not candidates for resection because of tumor size, location near major intrahepatic blood vessels precluding a margin-negative resection, multifocality, or inadequate hepatic function related to coexistent cirrhosis. Radiofrequency ablation (RFA) is an evolving technology being used to treat patients with unresectable primary and metastatic hepatic cancers. RFA produces coagulative necrosis of tumor through local tissue heating. Liver tumors are treated percutaneously, laparoscopically, or during laparotomy using ultrasonography to identify tumors and to guide placement of the RFA needle electrode. For tumors smaller than 2.0 cm in diameter, one or two deployments of the monopolar multiple array needle electrode is sufficient to produce complete coagulative necrosis of the tumor. However, with increasing size of the tumor, there is a concomitant increase in the number of deployments of the needle electrode and the overall time necessary to produce complete coagulative necrosis of the tumor. In general, RFA is a safe, well-tolerated, effective treatment for unresectable hepatic malignancies less than 6.0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies.

Original languageEnglish
Pages (from-to)165-176
Number of pages12
JournalMinerva Chirurgica
Volume57
Issue number2
Publication statusPublished - 2002

Fingerprint

Hepatocellular Carcinoma
Neoplasms
Needles
Electrodes
Necrosis
Liver
Technology
Liver Neoplasms
Heating
Laparotomy
Blood Vessels
Ultrasonography
Fibrosis
Therapeutics

Keywords

  • Carcinoma, hepatocellular, therapy
  • Catheter ablation
  • Liver neoplasms, secondary, therapy
  • Liver neoplasms, therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Radiofrequency ablation of hepatocellular carcinoma. / Curley, S. A.; Izzo, F.

In: Minerva Chirurgica, Vol. 57, No. 2, 2002, p. 165-176.

Research output: Contribution to journalArticle

Curley, S. A. ; Izzo, F. / Radiofrequency ablation of hepatocellular carcinoma. In: Minerva Chirurgica. 2002 ; Vol. 57, No. 2. pp. 165-176.
@article{92b9e6b2781b49f9afed50e823e3162f,
title = "Radiofrequency ablation of hepatocellular carcinoma",
abstract = "The majority of patients with primary or metastatic hepatic tumors are not candidates for resection because of tumor size, location near major intrahepatic blood vessels precluding a margin-negative resection, multifocality, or inadequate hepatic function related to coexistent cirrhosis. Radiofrequency ablation (RFA) is an evolving technology being used to treat patients with unresectable primary and metastatic hepatic cancers. RFA produces coagulative necrosis of tumor through local tissue heating. Liver tumors are treated percutaneously, laparoscopically, or during laparotomy using ultrasonography to identify tumors and to guide placement of the RFA needle electrode. For tumors smaller than 2.0 cm in diameter, one or two deployments of the monopolar multiple array needle electrode is sufficient to produce complete coagulative necrosis of the tumor. However, with increasing size of the tumor, there is a concomitant increase in the number of deployments of the needle electrode and the overall time necessary to produce complete coagulative necrosis of the tumor. In general, RFA is a safe, well-tolerated, effective treatment for unresectable hepatic malignancies less than 6.0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies.",
keywords = "Carcinoma, hepatocellular, therapy, Catheter ablation, Liver neoplasms, secondary, therapy, Liver neoplasms, therapy",
author = "Curley, {S. A.} and F. Izzo",
year = "2002",
language = "English",
volume = "57",
pages = "165--176",
journal = "Minerva Chirurgica",
issn = "0026-4733",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "2",

}

TY - JOUR

T1 - Radiofrequency ablation of hepatocellular carcinoma

AU - Curley, S. A.

AU - Izzo, F.

PY - 2002

Y1 - 2002

N2 - The majority of patients with primary or metastatic hepatic tumors are not candidates for resection because of tumor size, location near major intrahepatic blood vessels precluding a margin-negative resection, multifocality, or inadequate hepatic function related to coexistent cirrhosis. Radiofrequency ablation (RFA) is an evolving technology being used to treat patients with unresectable primary and metastatic hepatic cancers. RFA produces coagulative necrosis of tumor through local tissue heating. Liver tumors are treated percutaneously, laparoscopically, or during laparotomy using ultrasonography to identify tumors and to guide placement of the RFA needle electrode. For tumors smaller than 2.0 cm in diameter, one or two deployments of the monopolar multiple array needle electrode is sufficient to produce complete coagulative necrosis of the tumor. However, with increasing size of the tumor, there is a concomitant increase in the number of deployments of the needle electrode and the overall time necessary to produce complete coagulative necrosis of the tumor. In general, RFA is a safe, well-tolerated, effective treatment for unresectable hepatic malignancies less than 6.0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies.

AB - The majority of patients with primary or metastatic hepatic tumors are not candidates for resection because of tumor size, location near major intrahepatic blood vessels precluding a margin-negative resection, multifocality, or inadequate hepatic function related to coexistent cirrhosis. Radiofrequency ablation (RFA) is an evolving technology being used to treat patients with unresectable primary and metastatic hepatic cancers. RFA produces coagulative necrosis of tumor through local tissue heating. Liver tumors are treated percutaneously, laparoscopically, or during laparotomy using ultrasonography to identify tumors and to guide placement of the RFA needle electrode. For tumors smaller than 2.0 cm in diameter, one or two deployments of the monopolar multiple array needle electrode is sufficient to produce complete coagulative necrosis of the tumor. However, with increasing size of the tumor, there is a concomitant increase in the number of deployments of the needle electrode and the overall time necessary to produce complete coagulative necrosis of the tumor. In general, RFA is a safe, well-tolerated, effective treatment for unresectable hepatic malignancies less than 6.0 cm in diameter. Effective treatment of larger tumors awaits the development of more powerful, larger array monopolar and bipolar RFA technologies.

KW - Carcinoma, hepatocellular, therapy

KW - Catheter ablation

KW - Liver neoplasms, secondary, therapy

KW - Liver neoplasms, therapy

UR - http://www.scopus.com/inward/record.url?scp=0036251453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036251453&partnerID=8YFLogxK

M3 - Article

VL - 57

SP - 165

EP - 176

JO - Minerva Chirurgica

JF - Minerva Chirurgica

SN - 0026-4733

IS - 2

ER -